Studies have shown that using DPP4 inhibitors or GLP-1 mimetics is associated with a 36–60% lower risk of PD compared to other oral antidiabetic drugs, suggesting different therapeutic efficacy among different antidiabetic drugs (Brauer et al. 2020). Here, GLP1R is linked to Parkinson disease.